Form 4 for GILD Gilead Sciences
Accepted 2026-02-18 00:00:00 ET · period of report 2026-02-17 · accession 0001782135-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-18 | 2026-02-17 | GILD | Mercier Johanna | Chief Comm, Corp Aff Off | M - OptEx | $66.64 | +25.0K | 148.3K | +20% | +$1.67M |
| DM | 2026-02-18 | 2026-02-17 | GILD | Mercier Johanna | Chief Comm, Corp Aff Off | S - Sale+OE | $154.44 | -28.0K | 120.3K | -19% | -$4.32M |
| D | 2026-02-18 | 2026-02-17 | GILD | Mercier Johanna | Chief Comm, Corp Aff Off | M - OptEx | $0.00 | -25.0K | 48.1K | -34% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-17 | M | A | 25,000 | $66.64 | 148,288 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-17 | S | D | 18,405 | $154.18 | 129,883 | D | — | — | (F2) Sale prices for the transactions reported range from $153.565 to $154.56 Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. |
| 3 | Common | Common Stock | 2026-02-17 | S | D | 9,395 | $154.91 | 120,488 | D | — | — | (F3) Sale prices for the transactions reported range from $154.57 to $155.27 Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. |
| 4 | Common | Common Stock | 2026-02-17 | S | D | 200 | $155.62 | 120,288 | D | — | — | |
| 5 | Derivative | Non-qualified Stock Option (Right to Buy) | 2026-02-17 | M | D | 25,000 | $0.00 | 48,110 | D | $66.64 · — to 2029-07-24 | 25,000 Common Stock | (F4) The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |